Thu Dec 26 04:20:00 UTC 2024: ## Two Indian IPOs Close, Offering Investors Divergent Opportunities

**Mumbai, India – December 24, 2024** – The initial public offerings (IPOs) of Carraro India and Senores Pharmaceuticals concluded today, presenting investors with contrasting investment prospects. While Senores Pharmaceuticals’ IPO saw a 55% grey market premium, Carraro India’s offering attracted neither a premium nor a discount.

Carraro India, aiming to raise ₹1,250 crore through an offer for sale of 1.78 crore shares, saw positive analyst reviews. Bajaj Broking and Anand Rathi Research both recommended subscribing to the IPO, citing strong financial performance (FY24 profit after tax of ₹62.6 crore, a 29% year-on-year increase) and favorable valuation metrics. At the upper price band (₹704), the company’s P/E ratio is 45.83x, with an EV/EBITDA of 31.6x and a market cap of ₹4,002.3 crore.

Seniores Pharmaceuticals, seeking ₹582.11 crore through a combination of fresh shares and an offer for sale, also received positive assessments. Analysts highlighted the company’s strong growth (FY24 net profit of ₹32.7 crore, a 289% year-on-year increase) and the favorable outlook for the pharmaceutical sector. The upper price band of ₹391 results in a P/E ratio of 55x and a post-issue market cap of ₹1,800.6 crore. Despite the grey market premium, analysts recommend subscribing based on its valuation within the growing pharmaceutical market.

Both IPOs opened on December 20th, with share allotment expected on December 26th and listing on the BSE and NSE on December 30th. While Carraro India’s IPO is an entirely offer for sale by promoters and selling shareholders, Senores Pharmaceuticals’ IPO includes fresh share issuance. The significant difference in grey market performance underscores the diverse risk profiles of these two companies. Investors are advised to conduct thorough due diligence before making any investment decisions. The news also includes unrelated information regarding the resignation of India Cements Limited’s leadership following an acquisition by UltraTech Cement.

Read More